Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.48 HKD | 0.00% | +3.76% | -15.76% |
22/03 | Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023 | MT |
21/03 | Zylox-Tonbridge Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- With an enterprise value anticipated at 4.73 times the sales for the current fiscal year, the company turns out to be overvalued.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.76% | 438M | - | ||
+13.16% | 129B | A- | ||
-8.90% | 10.77B | A- | ||
+3.60% | 9.05B | C | ||
+19.75% | 7.38B | C | ||
+22.28% | 4.88B | B+ | ||
+7.55% | 3.41B | C- | ||
-0.21% | 3.07B | B- | ||
-4.80% | 2.24B | - | - | |
-4.72% | 2.12B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2190 Stock
- Ratings Zylox-Tonbridge Medical Technology Co., Ltd.